🔴 Illumina is trading 4.1% down today on profit-taking and broader biotech weakness

Illumina is trading 4.1% down at $196.74 on post-earnings profit-taking and broader biotech sector weakness.

• The company beat Q2 expectations and raised its 2026 revenue and EPS guidance, which initially sent shares higher in a strong post-earnings rally yesterday.
• Today's move appears to be a typical consolidation in a weak biotech tape, with the broader sector down over 3% despite no new negative company-specific news.